Ranolazine safely decreases ventricular and atrial fibrillation in timothy syndrome (LQT8)

PACE - Pacing and Clinical Electrophysiology

Volumn 35, Issue 3, 2012, Pages

  Shah, Dipak P ^a   Baez Escudero, Jose L ^a   Weisberg, Ian L ^a   Beshai, John F ^a   Burke, Martin C ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

electrophysiology clinical; long QT; pharmacology

Indexed keywords

CALCIUM CHANNEL L TYPE; METOPROLOL; METOPROLOL SUCCINATE; RANOLAZINE; VERAPAMIL;

ADULT; ARTICLE; CARDIAC CHANNELOPATHY; CARDIOVERSION; CASE REPORT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MALE; PHENOTYPE; QT INTERVAL; T WAVE; TIMOTHY SYNDROME; TIMOTY SYNDROME;

ACETANILIDES; ADULT; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DRUG THERAPY, COMBINATION; HUMANS; LONG QT SYNDROME; MALE; PIPERAZINES; SYNDACTYLY; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION; VERAPAMIL;

EID: 84857988682     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2010.02913.x     Document Type: Article

References (12)

1. Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, Napolitano C, et al,. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004; 119: 19-31. (Pubitemid 39349317)
2. Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, Beggs AH, Sanguinetti MC, et al,. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci USA 2005; 102: 8089-8096. (Pubitemid 40800048)
3. Jacobs A, Knight BP, McDonald KT, Burke MC,. Verapamil decreases ventricular tachyarrhythmias in a patient with Timothy syndrome (LQT8). Heart Rhythm 2006; 3: 967-970. (Pubitemid 44103509)
4. Sicouri S, Timothy KW, Zygmunt AC, Glass A, Goodrow RJ, Belardinelli L, Antzelevitch C,. Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: Effects of ranolazine. Heart Rhythm 2007; 4: 638-647. (Pubitemid 46630371)
5. Antzelevitch C, Belardinelli L, Wu L, Fraser H, Zygmunt AC, Burashnikov A, Di Diego JM, et al,. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther 2004; 9 (Suppl. 1): S65-S83. (Pubitemid 39334836)
6. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, et al,. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110: 904-910. (Pubitemid 39136212)
7. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C,. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: Differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007; 116: 1449-1457. (Pubitemid 47480635)
8. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, Wolff AA, et al,; MERLIN-TIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial. JAMA 2007; 297: 1775-1783. (Pubitemid 46658646)
9. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, et al,. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: Results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007; 116: 1647-1652. (Pubitemid 47537839)
10. Sicouri S, Glass A, Belardinelli L, Antzelevitch C,. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 2008; 5: 1019-1026.
11. Kumar K, Nearing BD, Carvas M, Nascimento BC, Acar M, Belardinelli L, Verrier RL,. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol 2009; 20: 796-802.
12. Murdock DK, Overton N, Kersten M, Kaliebe J, Devecchi F,. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J 2008; 8: 175-181.